Petosemtamab Shows “Clinically Meaningful Activity” in Advanced HNSCC
Petosemtamab can produce durable responses in patients with advanced head and neck squamous cell carcinoma, a phase 1/2 study suggests.
Petosemtamab can produce durable responses in patients with advanced head and neck squamous cell carcinoma, a phase 1/2 study suggests.
Adding ipilimumab to treatment with nivolumab does not improve response or survival outcomes in recurrent/metastatic HNSCC, a phase 2 trial suggests.
Ficlatuzumab plus cetuximab has demonstrated antitumor activity in pan-refractory, recurrent/metastatic head and neck squamous cell carcinoma.
Cancer survivors may be more likely to delay or forgo care if their treating clinician is of a different race, gender, or other identity, a new study suggests.
Adolescent and young adult patients diagnosed with cancer during pregnancy have a higher risk of adverse birth outcomes, a study suggests.
Patients with cancer experienced symptoms of PTSD during the first year of the COVID-19 pandemic, a French study suggests.
Oropharyngeal cancer patients who have discordant p16 and HPV status have worse prognosis than patients who have p16+/HPV+ disease, a study suggests.
Increasing social vulnerability is associated with significant decreases in surveillance and survival time among pediatric patients with head and neck cancers.
Among patients with head and neck cancer, smoking cessation for more than 10 years is associated with reduced overall mortality and cancer-specific mortality.
Adding docetaxel to radiation improves outcomes for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, a phase 2/3 trial suggests.